Neuland Laboratories (BOM:524558) Cash-to-Debt : 1.26 (As of Mar. 2024)

View and export this data going back to 1994. Start your Free Trial

What is Neuland Laboratories Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Neuland Laboratories's cash to debt ratio for the quarter that ended in Mar. 2024 was 1.26.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Neuland Laboratories could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Neuland Laboratories's Cash-to-Debt or its related term are showing as below:

BOM:524558' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 0.09 Max: 1.26
Current: 1.26

During the past 13 years, Neuland Laboratories's highest Cash to Debt Ratio was 1.26. The lowest was 0.03. And the median was 0.09.

BOM:524558's Cash-to-Debt is ranked better than
54.27% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs BOM:524558: 1.26

Neuland Laboratories Cash-to-Debt Historical Data

The historical data trend for Neuland Laboratories's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Neuland Laboratories Cash-to-Debt Chart

Neuland Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash-to-Debt

Get a 7-Day Free Trial

0.11

0.06

0.04

0.35

1.26

Neuland Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.35	N/A	1.40	N/A	1.26

Competitive Comparison of Neuland Laboratories's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuland Laboratories's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Neuland Laboratories's Cash-to-Debt falls into.

Neuland Laboratories Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Neuland Laboratories's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1196.833	/	(412.656	+	541.24)
	=	1.25

Neuland Laboratories's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1196.833	/	(412.656	+	541.24)
	=	1.25

Neuland Laboratories (BOM:524558) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Neuland Laboratories Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Neuland Laboratories's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Neuland Laboratories (BOM:524558) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neuland Laboratories Ltd (BOM:524558) » Definitions » Cash-to-Debt

Traded in Other Exchanges

NEULANDLAB:India

Address

Road No. 82, Jubilee Hills, Plot No. 573A-III, Phoenix IVY Building, 11th Floor (5th Office Level), Hyderabad, TG, IND, 500033

Website

https://www.neulandlabs.com

Neuland Laboratories Ltd is a manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end solution provider for the pharmaceutical industry's chemistry needs in Hyderabad. Geographically, it derives a majority of revenue from North America and also has a presence in India, Europe, and Rest of the world.

Neuland Laboratories (BOM:524558) Headlines

No Headlines